More so than rheumatoid arthritis (RA), psoriasis (PsO) and psoriatic arthritis (PsA) are associated with liver disease, particularly non-alcoholic fatty liver disease (NAFLD) and cirrhosis, and this was true even among patients without systemic therapy (ST) exposure, according to a recent study. Researchers performed a cohort study among patients with PsO, PsA, or RA and matched controls in The Health Improvement Network from 1994-2014. Outcomes of interest were any liver disease, NAFLD, and cirrhosis (any etiology). They found:
- Among patients with psoriasis (n=197,130), PsA (n=12,308), RA (n=54,251), and matched controls (n=1,279,754), the adjusted hazard ratios for any liver disease were elevated among patients with PsO, PsA, and RA without a ST but not elevated in RA patients prescribed a ST.
- Incident NAFLD was highest in patients with PsO prescribed a ST and PsA with a ST.
- Risk of cirrhosis was highest among patients with PsO with a ST and PsA without a ST.
- Additionally, the prevalence of liver disease and cirrhosis increased in a stepwise fashion with increasing body surface area affected by PsO.
Ogdie A, Grewal SK, Noe MH, et al. Risk of incident liver disease in patients with psoriasis, psoriatic arthritis, and rheumatoid arthritis: A population-based study. [Published online ahead of print November 2, 2017]. J Invest Dermatol. doi:10.1016/j.jid.2017.10.024.
This Week's Must Reads
Sexual Minority Men and Tanning Behavior Examined, JAMA Dermatology; ePub 2018 Feb 28; Gao, et al
Patients with HS Have Higher Substance Abuse Odds, J Am Acad Dermatol; ePub 2018 Feb 27; Garg, et al
Patient QOL Fluctuates Before & After Mohs Surgery, J Am Acad Dermatol; ePub 2018 Mar 5; Zhang, et al
Sex-Specific Prognostic Implications in Melanoma, J Am Acad Dermatol; ePub 2018 Mar 5; Sinnamon, et al
Trends in Atopic Dermatitis Management, J Drugs Dermatol; 2018 Feb; He, Feldman, et al
Must Reads in Psoriasis
Treatment Preferences of Patients with Psoriasis , Arch Dermatolog Treat; ePub 2018 Feb 13; Florek, et al
TB Risk in Psoriasis Patients Using TNF Inhibitors , J Dermatolog Treat; ePub 2018 Feb 19; Lee, et al
FDA Approves Label Update for Cosentyx, Novartis news release; 2018 Feb 8
Childhood Psoriasis, Obesity, and Comorbidities, JAMA Dermatology; ePub 2018 Jan 10; Tollefson, et al
FDA Approves New Pfizer Biosimilar Ixifi, Pfizer news release; 2017 Dec 13